---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-24-000088"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:55:34.451631+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Johnson & Johnson Q3 sales up 5.2% to $22.5B; GAAP EPS down 34% to $1.11 on higher R&D and other charges

## Summary
- Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.
- GAAP net earnings from continuing ops $2.69B ($1.11 diluted EPS), down 37.5% YoY; adjusted net earnings $5.88B ($2.42 adjusted EPS), down 13.3%.
- R&D expense jumped 43.7% to $4.95B (22.0% of sales); other expense net $1.80B vs $0.50B in prior year.
- GAAP effective tax rate 19.3% vs 17.4%; adjusted tax rate 19.3% vs 15.6%.
- Discontinued ops had no contribution vs $21.7B in prior year (related to Kenvue separation).

## SEC filing metadata
- accession: 0000200406-24-000088
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040624000088/0000200406-24-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040624000088/jnj-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-24-000088
- JSON: https://secwatch.observer/filing/0000200406-24-000088.json
- Plain text: https://secwatch.observer/filing/0000200406-24-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.